Skip to main content

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Written by Customer Service on . Posted in Public Companies.

WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer.

“Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.”

Ms. Hensley most recently served as senior vice president, assistant general counsel and chief compliance officer at Seres Therapeutics, Inc., where she oversaw all corporate legal and compliance matters, including capital markets and licensing transactions, clinical development and commercial launch activities, partnership/collaboration management, and FDA and healthcare regulatory compliance matters. Previously, Ms. Hensley was a corporate associate in the Boston office of Latham & Watkins, where she represented public and private companies in biotechnology and other industries across a range of capital markets and strategic transactions throughout their lifecycle. She received her B.A. in economics from the University of Texas at Austin and her J.D. from the Boston University School of Law.

“I am thrilled to join the Xilio team at this pivotal moment in the company’s growth and look forward to helping to advance Xilio’s promising pipeline of novel, tumor-activated immuno-oncology therapies,” said Ms. Hensley.

About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecifics and immune cell engagers. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Investor and Media Contact 
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.